58 / 74 · 0:55 · Original AXON film
Bremelanotide / PT-141
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Bremelanotide / PT-141
Bremelanotide, also known as PT-141, is a melanocortin receptor agonist. Its approved US product, Vyleesi, has a specific sexual-health indication. [1]
A defined HSDD indication
The label covers acquired, generalized hypoactive sexual desire disorder in premenopausal women under defined conditions. It is not an approval for general sexual-performance enhancement. [1]
Trials assess desire and distress
Two randomized, placebo-controlled trials assessed desire and associated distress. Nausea was common, and the label includes important warnings about blood pressure and skin pigmentation. [1]
Product, route, and safety limits
Clinical evidence for the approved product does not validate a differently formulated spray or research vial. The population, diagnostic criteria, route, and safety restrictions remain essential parts of interpreting the findings. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Vyleesi prescribing information, revised March 2024 →Bremelanotide receptor class, approved indication, two randomized trials, endpoints, common nausea, blood-pressure and pigmentation warnings, and limitations of use.
